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Abstract
Dendritic cells [DCs] are potent antigen presenting cells [APC], which plays a vital role in immune system by 
detecting and capturing pathogens in the body. DCs perform a pivotal role in induction of T cell response. Regulation 
of immune response can be achieved by specific antigen [Ag] delivery to DCs. A delivery system that can efficiently 
target and present Ags to DCs for the purpose of anti-tumour activity is currently a topic of significant research 
interest. DCs are receiving attention due to their key role in anti cancer host response and due to their adjuvanic 
property in tumour vaccines. Role of toll like receptors [TLR] in innate immune system and their part in eventual 
stimulation of adaptive immunity is exploited to develop vaccines. TLR agonists in conjugation with vaccines are 
shown to increase therapeutic efficacy in some cases. TLRs also play a vital role in protecting the cornea from 
invading pathogens. Due to adverse effects in the treatment of ocular inflammations, cancer and in viral infections, 
an alternate approach such as the use of TLRs will solve the inquisitive question regarding side effects. The intended 
delivery is attained by the use of nanoparticles which in turn leads to prolonged half-life in the body. Co-delivery 
of Ags, TLRs and immunomodulators using nanoparticles has been demonstrated to elicit potent cellular immune 
responses and are currently under development of clinically applicable immunisations and vaccines. 
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Introduction
In spite of all the efforts to suppress the spread of infectious diseases 
and cancer by the biomedical sector, they still represent the major cause 
of death. According to world health organisation [WHO], cancer is 
responsible for one third of lost years of life [1]. Most cancers are treated 
by combination of standard therapies like surgery and chemotherapy. 
Conventional therapies not only target tumors cells but also healthy 
cells as the drug does not discriminate the cell types. To overcome these 
obstacles, targeted nanomedicine is designed for the delivery of drugs 
selectively to tumor cells. Therapeutic vaccination against tumors 
proved far more stringent than prevention. The goldilocks approach 
of establishing tumor immunity with the molecularly designed 
nanoweapons would aid in the homeostatic induction of immune 
cells and other host effector molecules. Toll like receptors [TLRs] are 
one such crucial sensors of innate immune system identified as key 
targets in tumor immunology. TLRs are pattern recognition receptors 
[PRR] which recognise antigens [Ag] and initiate the immune cell 
cascade. The use of TLRs as molecular targets for intensifying immune 
response provides a substantial advance in the field of therapeutics. 
Pathogen mimicking nanoparticles capable of interacting with 
dendritic cells [DCs] in conjugation with TLR regulates the immune 
system. Amalgamating nanocarriers with the agonists increases the 
levels of proinflammatory cytokines, chemotactic factors and type 1 
Interferon [IFN]. This response eventually elevates adaptive immunity 
and further vaccine responses, to combat malignant cells. On the 
basis of pharmacokinetics profile, either agonist or antagonists are 
used therapeutically for various diseases. Clinical trials are imperative 
in using these agents to collect safety and efficacious data for health 
interventions. This paper will explore the horizons of TLR utilisation 
in cancer biology, corneal inflammations and in viral infections to up-
regulate immunosuppressive state of humans. 
TLR and immune system
The innate immune system relies on the recognition of simple 
molecules and regular patterns displayed by pathogens and many 
microorganisms which are not seen on the body’s own cells [3]. 
These structures, known as pathogen associated molecular patterns 
(PAMPs), are recognised by receptors known as PRRs. The innate 
immune system as well as the adaptive immune system relies heavily 
on the function of PRRs. However, recognition of non-pathogenic and 
commensal microflora by PRR is largely unknown [4]. Presumably, 
compartmentalization (confinement of commensal microflora to 
luminal side of intestinal epithelium), transforming growth factor 
(TGF-β) and interleukin (IL-10) play an important role in this process. 
PAMP’s are highly conserved throughout the evolution and are less 
destined for mutation since they are vital for survival of microbes. Three 
main features of PAMPs make them ideal targets for innate immune 
system. First, they are produced only by microbes and not by host 
cells. Second, they are invariant between microorganisms of a given 
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class and thirdly, PAMPs are essential for survival of the microbial 
flora [5]. There are a variety of different types of PRRs, where TLRs 
are one major group. TLRs belong to type I transmembrane receptors 
characterised by the presence of leucine-rich repeat domain (LRR) 
and an intracellular Toll/IL-1 receptor domain (TIR). They appear to 
be the one of the most conserved components of the immune system 
with basic signaling receptors for the innate immune stimulation. 
Its expression is ubiquitous from epithelial to immunocompetent 
cells [6,7]. Associated with the TIR domain are the presence of five 
adaptors myeloid differentiation MyD88, MyD88-adaptor like (Mal), 
TIR-domain containing adaptor protein inducing IFN-β (TRIF), TRIF 
related adaptor molecule (TRAM) and sterile α- and armadillo motif 
containing protein (SARM) [8]. These adaptor molecules activate 
intracellular molecules including protein kinases to orchestrate 
the inflammatory response [9]. The human TLR family is known to 
consist of 10 members with this number likely to increase as relatively 
little attention has been given to them in the past  [3,10]. TLR 1 and 
TLR 2 dimerization responds to triacyl peptides [11] whereas, TLR 
2/TLR 6 recognizes diacyl peptides [12]. TLR 2 in combination with 
lectin receptors enables the recognition of fungal cell wall component 
zymosan [14]. Double stranded RNA and some synthetic RNA 
moieties are ligands for TLR 3 [13]. TLR 4 serves as a specific receptor 
for lipopolysaccharide (LPS), the most powerful microbial stimulant of 
innate immunity. By promoting the release of inflammatory cytokines, 
LPS also mobilize the innate and adaptive immune response [15]. 
TLR 5 has been shown to recognise conserved domains of flagellin (a 
monomeric constituent of flagella). TLR 5 is reported to be present 
on basolateral side of intestinal epithelial cells and in sub epithelial 
compartment necessating the balance of homeostasis at the mucosal 
layer [16]. Down the lane, TLR 7, TLR 8 and TLR 9 are reported 
for recognition of ssRNA from viruses. The host ssRNA are not 
recognised as foreign by TLR 7/8 due to the subcellular expression of 
these TLRs in the endosomal compartment. TLR7/8 also recognises 
synthetic compounds: imidazoquinolines used for treating genital 
warts and loxoribine as an immunostimulant [17]. TLR 9 is a receptor 
of ummethylated CpG DNA motifs which are the characteristics of a 
bacterial genome [18]. CpG motifs with GACGTT sequence stimulate 
mouse TLR 9 while with the core sequence GTCGTT optimally induce 
human TLR 9 [19]. TLR 11 gene present in animals are resistant to 
uropathogenic strains of E.Coli. Human kidney also appears to contain 
TLR 11 gene yet the protein is not expressed [20]. Animals are shown 
to explicit TLR 12 and TLR 13 with no counterpart expression in 
humans [21]. TLRs efficiently converts immature DCs into mature 
DCs. Maturation of DCs are marked by the increased expression of 
cytokines, major histocompatibility complex [MHC] class I and 
class II, tumour necrosis factor [TNF-α, IL-1, IL-6, IL-8, IL-12 and 
co-stimulatory molecules like CD40, CD80 and CD86. Once the 
maturation is complete DCs migrate to secondary lymphoid organs 
(lymph node) for presentation of Ag to T cells. Chemokine CCR7 is 
responsible for migration of DCs to lymph node and also for pinocytic 
activity. Immature DCs are adherent to actin cytoskeleton and once they 
encounter Ag, actin gets polarized and so DCs detach from actin fibres. 
The increased phagocytic activity of DC is regulated by extracellular 
signal regulated protein kinase (ERK1/2) and p38α mitogen activated 
kinase. Ag coupled with TLR is much preferred to be endocytosed by 
APCs. In addition to that cross presentation of Ag is more when it 
has been coupled with TLRs [9]. When an Ag is encountered by DC it 
migrates to lymph node and present to naive CD4+ T cells and CD8+ 
cytotoxic cells. Following this, naive CD4+ T cells differentiate into 
memory helper T cells which in turn are responsible for differentiation 
and expansion of CD8+, cytotoxic T lymphocytes [CTL] and B cells 
[8]. Other immune cells such as macrophages, mast cells, eosinophils, 
neutrophils etc also recognise Ag through TLRs.
TLRs and adjuvanticity
Adjuvants are compounds known to enhance the magnitude and 
quality of immune response to antigens with minimal toxic profile. 
The reduction in the amount of Ag with increased immunogenicity 
makes them ideal for a successful vaccination strategy. Interest in 
vaccine adjuvants has been growing rapidly due to the presence of 
only few FDA approved adjuvants in the market. Alum was the first 
adjuvant approved by FDA. Recently MF59 has been approved in 
Europe for flu vaccine (Fluad, Novartis vaccine) and ASO4 for viral 
vaccines [22,23]. Addition of adjuvants to vaccines may substantially 
decrease the amount of Ag to be administered. While there have 
been spectacular successes in tumor targeted immunotherapy, the 
need for tumor vaccines top the list in clinical oncology. There is still 
a degree of pessimism for the use of adjuvants for treating cancer. 
To augment this, multiple adjuvants have been developed ranging 
from live-attenuated strains to molecularly defined compositions to 
elicit receptor associated immune response. Cell wall skeleton from 
Mycobacterium bovis (Bacille Calmette-Guerin vaccine) has been 
used as an adjuvant since, the cell wall of this bacterium comprises 
of NOD-2 agonist muramyl dipeptide. The inflammatory response to 
BCG antigens is processed via TLR 2 and TLR 4. Lipoarabinomannan 
and lipomannan from this bacterium activates the immune cells for 
the production of TNF and interleukin (IL-12) [24]. Though the use 
of BCG stands as an age old concept, its clinical usage is limited since 
the synthetic production is highly complex. Hence the focus is diverted 
towards development of synthetic agonists. The synthetic component 
derived from Staphylococcus aureus, 16 S-[2, 3-bis (palmitoyl)propyl]
cysteine (Pam2) lipopeptides is shown to activate DCs and natural 
killer [NK] cells for the production of  interferon [IFN-γ] [25]. With 
the incorporation of RGDS peptide for the effective cell penetration, 
their use as an adjuvant has surpassed the disadvantages of commercial 
adjuvants in use. The Pam2 lipopeptides have two palmitoyl bases 
attached to two separate peptide sequences for the determination 
of TLR 2 agonist activity [26]. The mucosal adjuvant effect of TLR 3 
dsRNA agonist produces high concentration of IgA and also protects 
from the recurrent viral infections. Due to the toxicity profile of poly (I: 
C), a chemically modified form [PolyI:C12U ] of the above formulation 
was synthesized. Additionally, PolyI:C12U [AMPLIGEN] is used as an 
adjuvant for mucosal vaccine for avian H5N1 virus [27]. In regard to 
tumor therapy, poly (I: C) has been used as a cancer adjuvant vaccine 
since they can effectively activate DCs and NK cells. The main function 
of poly (I: C) is to boost the maturation of DCs for further priming 
and clonal expansion of antigen specific T cell response. Interestingly, 
the TLR 3 agonist acts through diverse accessory molecules rather 
than acting via DCs alone [28]. A recent study by McCartney showed 
the involvement of NK cells, IFN-α and IL-12 associated with the 
TLR 3 signaling pathway activation through poly (I: C) agonist [29]. 
Cervarix, a vaccine against human papilloma virus is formulated 
with monophosphoryl lipid A [MPL], a TLR 4 targeted adjuvant for 
promoting the immune response. The clinical grade form of MPLA 
has low toxic profile of about 0.1%. [30]. TLR 5 agonist, flagellin is 
used as an adjuvant for the delivery of recombinant hemagglutinin. 
The use of flagellin to adjuvant influenza vaccines via TLR 5 innate 
immune pathway trigger a cascade of multitudinal transcriptional 
events responsible for adaptive immunity. [31,32]. Commonly used 
agonists for TLR 7 are imiquimoid and resiquimod. Very recently, a 
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guanosine analog 7-allyl-7,8-dihydro-8-oxo-guanosine (loxoribine) 
has been identified as a TLR 7 agonist. They activate plasmacytoid DCs 
and B cells for the induction of IFN-α and IFN-regulated cytokines 
[33]. A very similar pattern of activating myeloid DCs, monocytes and 
monocytes derived DCs for the release of TNF-α, IL-12 and macrophage 
inflammatory protein – 1 alpha is through TLR 8 agonist – VTX-
2337 which is in phase I study. Due to its high adjuvanting property, 
it has been used to treat solid tumors or lymphoma [34]. Synthetic 
and natural oligodeoxynucleotides containing specific motifs of CpG 
dinucleotide are potent immunostimulatory agents for activation of 
TLR 9 pathway [35]. They directly induce the differentiation of B cells 
into antibody secreting plasma cells. On the other hand, release of 
IFN-α from immature DCs activates NK cells for the action of tumor 
cell lysis. Mature DCs capture the released tumor Ags and process it 
through major histocompatibility complex [MHC] which in turn leads 
to the migration of DCs to lymph nodes for the delivery of processed 
Ags to lymphocytes initiating Th1 response [36]. The activity and safety 
of these molecularly defined adjuvants and formulations has provided 
support for the concept of antitumor and antiviral immunity with 
reduced adverse effects. 
Sorting of toll signals via TLR adaptors
The downstream pathways of TLR signaling require two major 
adaptor proteins MyD88 and TRIF. The utilisation of TIR domain 
containing adapter protein or Mal [TIRAP] and TRIF related adaptor 
molecule [TRAM] has been associated with TLR 2 and TLR 4. Several 
transcriptional regulations involving nuclear factor [NF-kB], activator 
protein-1 [AP-1], interferon regulatory factor 3 and 7 [IRF] constitute 
pleiotropic effects with tightly regulated gateways for gene modulation 
[37]. In regard to MyD88 dependent pathway, the adaptor molecule 
MyD88 possesses TIR domain in C terminal and death domain in 
N-terminal portion. Associating with TIR domains of TLRs, MyD88 
recruits IL-1 receptor associated kinase (IRAK). After phosphorylation 
it interacts with TNF receptor associated factor [TRAF 6] for the 
activation of two crucial signaling pathways JNK and NF-kB [38]. In 
the case of MyD88 independent pathway, LPS induces the activation 
of NF-kB and JNK through TLR 4 stimulation. Precisely, IFN-
induced protein 10 [IP-10] and glucocorticoid attenuated response 
gene [GARG 16] were induced for the initiation of immune cascades. 
They also augment surface activation markers like CD40, CD80 or 
CD 86 in dendritic cells [39]. The molecular stack of 232 aminoacid 
cytoplasmic protein is attributed to TIRAP adaptor molecule which 
strongly influences the NF-kB promoter equivalent to MyD88 [40]. 
MicroRNAs [miRNA] have recently been identified as important 
regulators of TLRs. The miR155 is known to target TLR 2, TLR 3, TLR 
4 and TLR 9 through MyD88 and adaptor molecules in monocytes, 
DCs and macrophages. Similarly, miR125b, miR147, miR223 and 
miR27b regulate TLR 4 by activating NF-kB in cholangiocytes, alveolar 
macrophages, inflamed lung tissues and in peritoneal macrophages 
respectively [41]. Despite the wealth of information regarding miRNA 
in manipulation of TLR signaling is known, complete pathway of TLR 
signaling remains unexplored indicating the involvement of additional 
gene products for cell specific expression. 
Corneal immunity
The delicate visual organ that is responsible for vision is highly 
vulnerable to immunological inflammation and microbes. The 
features that account for the constructive action of vision are 1) ocular 
barriers 2) absence of lymphatic drainage pathways 3) presence of 
immunomodulatory factors and 4) presence of APCs. Presence and 
utilisation of TLRs for improving ocular immunity will quench the 
thirst for corneal haze. 
Corneal TLR
Cornea is an ideal model for evaluating in vivo angiogenesis 
in cancer. The introduction of targets initiates angiogenesis, thus 
providing a platform for tumour study [42]. Rabbit eyes are excellent 
prototype for such studies. Recently research on mice eyes has also 
been initiated. Basically, cornea  is a transparent, dome-shaped surface, 
with two specialized function i) protective barrier between the external 
environment and internal milieu, ii) constitutes the main refractive 
element of visual system [42,43]. It is made of three major layers: 
epithelial, stromal and endothelial cells. Corneal epithelium extends 
a barrier, and restricts entry of pathogens into eye [43]. It has an 
ability to detect and fight microbial pathogens [44-46]. Nonetheless, 
corneal innate immunity involves many other components such as 
keratocytes, corneal fibroblasts, langerhans cells (dendritic cells) and 
immunoglobulins (IgG and IgA) [45]. It has been demonstrated that 
injury or infections to the cornea triggers an immune reaction which 
leads to recruitment of polymorphonuclear cells, lymphocytes, and 
fibroblasts following the release of chemotactic factors such as IL-8 
and cationic antimicrobial protein of 37 kD from corneal epithelium 
(Figure 1). Expression of TLR 1 to 10 is observed in corneal epithelium 
from patients with ocular diseases and also from human cadavers. 
However, not all subjects express all the TLRs. TLR 7 and TLR 8 
expression is very low in some cases [46]. The constitutive as well as 
inducible expression of various TLRs such as TLR2, TLR3, TLR4, 
TLR5, TLR9 and TLR10 have been seen in corneal epithelium in vitro 
and in vivo [44-46]. Corneal expression of TLRs is mediated during 
inflammatory disorders such as atopic keratoconjuctivitis, sjogren’s 
syndrome as well as during bacterial, viral and fungal infections [47]. 
TLR2 and TLR4 expression in cornea functions as a gram-positive 
and gram-negative bacteria [Pseudomonas aeruginosa] sensor [48]. 
Flagellin protein present in flagella [Pseudomonas] is a ligand for TLR 5 
[49]. Lipoprotein also binds the TLR2/1 dimer albeit from mycoplasma 
[50]. TLR7 has been shown to recognize Herpes Simplex Virus [HSV-
1] infection and likely involved in corneal innate immune responses 
in herpetic keratitis [43]. TLR9 recognises CpG rich DNA viruses as 
well as gram negative and gram positive bacteria [51]. Upregulation 
of defensins, small peptide that target bacterial cell wall has been 
recognised after activation by TLR, thus solidifying the importance 
of TLR [43]. Although the corneal inflammatory response via TLR 
signalling is vital for efficient removal of pathogenic microbial agents, 
an inadequately regulated proinflammatory cytokine production may 
result in  inflammatory responses which would lead to  corneal scarring 
and loss of vision altogether. In some cases, constant activation of 
TLR leads to other corneal inflammatory conditions such as dry eye 
syndrome and allergy. Thus a TLR decelerator is necessary to curtail 
the proinflammatory state. Although information regarding this 
indispensable process is scarce, negative regulators of TLRs induce 
single Ig IL-1 related molecule [SIGIRR] and ST2 [member of TIR 
family which do not activate NF-kB] [52]. These two molecules act 
by impounding on MyD88 and IRAK [IL-1R associated kinases] [47]. 
SIGIRR or ST2 blockade leads to serious bacterial corneal diseases. This 
strongly suggests that even though TLR signaling is necessary to fight 
against pathogens, if the signaling activity is unchecked by SIGIRR 
or ST2 serious corneal injury develops. This poses a most formidable 
conundrum of how to modulate TLR signaling in such a manner so as 
to maximize surveillance and disposal of foreign invaders while curbing 
potential damage to self. Ocular epithelial cells are very selective in 
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responding to microbial products by discriminating the pathogenic 
bacteria from non-pathogenic ones. Corneal opaqueness which is 
often referred as corneal haze results in patients who are treated for 
myopia, hyperopia and astigmatism. Sometimes it disappears within 
6-9 months but not in all cases. Wolbachia, an endosymbiotic bacteria 
lives in a parasite Onchocerca volvulus which mainly infects Africans 
[53]. During these infestations, the parasite resides in subcutaneous 
nodules and releases millions of microfilariae which migrate to anterior 
chamber of eye. As a result of immune defense, several chemokines 
and cytokines are released to combat the infection. As a result of the 
release of CXCR2, a chemokine produced by stromal cells, neutrophils 
are recruited to the site [54]. This phenomenon results in the 
transformation of fibroblast present in stromal layer to myofibroblast 
with high expression of smooth muscle actin. These myofibroblasts 
accumulate extracellular matrix and matrix metalloproteins in the 
infection site to alter biophysical environment of the infectious site. 
Corneal opacity is also caused by decreased expression of corneal 
crystallins by activated fibroblasts [55]. A Major threat to aboriginals in 
Australia is Trachoma infection which leads to morbidity and blindness 
(Figure 1). In most cases, active trachoma in the conjunctiva heals 
without any loss of vision. On the contrary, chronic infection leads 
to block of lachrymal ductules leading to loss of tears thus creating a 
platform for secondary infections. Apparently vaccines produced only 
short term immunity and hence TLR agonist can be used against this 
infection. No particular synthetic TLR agonist has been synthesized 
till now for Trachoma yet LPS can be an alternate agonist to some 
extent [56-58]. Approach to corneal haze with nanotechnology is in 
its infancy. Various nanoformulations comprising TLR agonist and 
antagonists have been used. Studies by Ueta clearly show that corneal 
epithelial cells engage TLR 3 to produce proinflammatory factors in 
response to poly (I: C), a viral mimic [59]. 
Enhancement of tumor immunity by augmenting DCs
Current cancer vaccine suffers from poorly quantifiable T-cell 
response and immunosuppressive tumour microenvironment. So 
there is a need to improvise the vaccine engineering such that lasting 
Figure 1: Cornea is made of three layers such as outer epithelium, middle stromal cells and inner endothelium cells. Inflammation of eye can lead to serious loss of 
vision and is a leading cause of blindness. Immune responses in the eye are modulated by tissue resident cells. Cornea is exposed to microbes constantly. Entry of 
bacteria into the eye results in rapid proliferation since vitreous acts an excellent medium. Ocular barrier breakdown and inflammatory cell recruitment is expected due 
to initiation of inflammatory products cascade. Though lysozyme secretion catalyzes the hydrolysis of cell membrane, some pathogenic bacteria possess high in vitro 
resistance to lysozyme. When they breach the epithelial layer, TLRs of ocular cells recognise the Ag and secrete proinflammatory cytokines like IL-8, IL-1 and TNF- α. 
These chemokines attract DCs to the infection site. Release of TGF-β, IL and CXC-2 recruits neutrophils to the infected site. This process results in transformation 
of normal fibroblast to myofibroblast, thus reducing corneal transparency. Once the sentinels take up the Ag, they present it to NK cells which then activate T-helper 
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immune response is acquired with reversal of immunosuppression 
in tumour environment. Customized nanoparticles are designed to 
meet the expectations of targeted delivery with prolonged half-life 
in the body [55]. Nanotechnology based drug delivery uses a variety 
of nanovectors including liposomes, micelles, dendrimers, protein 
nanoparticles, ceramic nanoparticles, polymeric nanoparticles and 
metallic nanoparticles [60,61]. These are used to carry and deliver drugs 
specifically to the site of tumour. These drug delivery systems generally 
consist of three parts; the core material, a therapeutic drug and surface 
modifiers [62]. The surface engineering involves functionalisation with 
ligands such as peptides, aptamer, antibodies, nucleic acids or small 
molecules in order to increase specificity and efficacy of treatments 
[63]. Anti tumour drugs with low molecular weight tend to distribute 
throughout the body by systemic circulation, yet diffuse from the 
cancerous tissue easily reducing the residence time and eventually get 
eliminated by renal filtration. Therefore, high molecular weight polymer 
like polyethylene glycol [PEG] is conjugated to drug molecules, so that 
the drug tends to stay within the leaky vasculature of tumour cells. 
Non PEGlyated particles have short retention time in the systemic 
circulation [64,65]. Tumour targeting can be passive or active [66]. 
Passive targeting takes advantage of leaky endothelial cells, which are 
from fast growing cancerous tissue, so that nanoparticles can enter and 
accumulate in the interstitial space. This method is more primitive as 
it relies on diffusion [62]. A more favourable approach can be achieved 
if the nanoparticles specifically target tumour cells and are activated 
once the target is reached. Active targeting involves the conjugation of 
drug to the nanoparticle of a targeting constituent to provide specific 
accumulation of nanoparticle at the tumour site [67,68]. Tumor cells 
overexpress receptors or Ags, which can be helpful for the efficient 
uptake of drugs via receptor-mediated endocytosis. Various ligands 
such as proteins, antibodies, carbohydrates, nucleic acids and aptamers 
are used for targeted delivery [69]. Imaging the nanoparticles is the next 
hurdle in the field of therapeutics. The development of multifunctional 
nanoparticles in which drug delivery, sensing and imaging capabilities 
are integrated is known to be a powerful system. Nanoparticles are 
targeted to APCs for enhancement of tumor immunity. Specific 
targeting of DCs through nanoparticles enhances the proliferation of 
Ag specific CD8 and CD4 cells [70,71]. 
After phagocytosis, when nanoformulation gets dislodged from 
endosomes, Ag or drug is released. The cytosolic Ag is then recognised 
by MHC class I molecule on DCs leading to cross presentation. 
Hamdy et al. examined that co-delivery of ovalbumin and 7 acyl lipid 
A in PLGA-nanoparticle augmented DC maturation and ovalbumin-
specific CD4+ and CD8+ T-cell proliferation responses. Following 
up this study, encapsulated ovalbumin and TLR 9 in PLGA showed 
tumor regression of about 80% in animals with ovalbumin expressing 
B16 melanoma. Mutual activation of DC and NK cells in the presence 
of TLR agonist forms the basis for tumour suppression [72]. Pham et 
al experimented in TLR 4 agonist to enhance the maturation of DCs 
by NK cells. Lower doses of cyclophosphamide and IL-12 promoted 
the articulation of tumor specific CTL and several co-stimulatory 
molecules. This vaccine model was found to inhibit mouse colon 
cancer [CT-26] [71]. A research group headed by Conforti et al. [50] 
revealed that TLR 3 stimulates the epithelial cells of tumor to intiate 
chemokine cascade. This fundamental knowledge gave rise to use of 
poly (A:U) to activate CCL5 and CXCL10 [Chemotactic cytokines]. 
Systemic administration of poly (A:U) displayed immunoadjuvant 
effect through TLR3/TLR7. Both these TLRs are essential for clonal 
selection of Ag specific CD8+ T cells. When poly (A:U) is combined 
with vaccine or chemotherapy the anti tumour titre was  elevated [73].
Cell specific targeting via mannose receptors
In an early study, cell specific ligands for targeted drug delivery 
were investigated using mannan coated nanoparticles [74]. DCs and 
macrophages both express mannose receptors (ManR). ManR are 
PRRs which recognise glycoproteins present in fungal cell walls, viruses 
and in prokaryotes. ManR is a scavenging receptor which recycles back 
to the cell surface where it can be employed in consecutive cycles for 
internalisation. The nanoparticles coated with mannan ligands can be 
used for targeting APCs to enhance the particle uptake for increasing 
the anti tumor titre [74]. Without addition of the mannan receptor 
ligands on the nanoparticles, Ag recognition is limited with low T cell 
responses. Binding and cellular uptake was improved from 5% of the 
uncoated nanoparticles to about 53% with mannan coated nanoparticles, 
again demonstrating the advantage of cell specific binding in targeted 
delivery systems [75]. To augment anti tumor response through IL-12 
gene therapy, mannosylated chitosan nanoparticles are employed for 
effective endocytosis [76]. Additionally, mannosylated chitosan greatly 
increase the Ag availability to the macrophages and DCs for better 
induction of IFN-γ release [77]. Similiar to TLRs, ManR also provide a 
link between innate and adaptive immunity. 
Multifactorial nanoparticles used in various studies
Biodegradable nanoparticles are engineered to imitate the surface 
properties of pathogens to enhance the property of phagocytosis [2,78]. 
Diwan et al. fabricated nanoparticles from a biodegradable copolymer 
(PLGA) to deliver cancer Ags to DCs for promoting strong anticancer T 
cell response [78]. Two Ags, tetanus toxoid and MUC1 [mucin peptide], 
along with immunomodulators were studied. The Ag was capable of 
binding to both MHC class I and class II molecules, for activating 
CD4+ and CD8+ T cells. Two other immunomodulators like MPLA 
and CpG were studied for effective tumor immunity. MPLA, a ligand 
for TLR4, was found to have the strongest effect on T cell activation. 
CpG oligonucleotides following phagocytosis activated TLR9 pathway 
[78]. Conclusively, Ags delivered in the form of nanoparticles are very 
effective in T cell activation when compared to soluble Ag [60]. It was 
noted that Ag presentation by both MHC molecules as well as TLR 
co stimulatory signaling are required for the potent activation of Ag 
specific primary T cells, underlining the significance of co-delivery of 
immunostimulatory molecules [79,80]. 
Ideally, tumour associated Ag [TSA] specific cytotoxic T cells are 
generated after the efficient delivery of TSA to APCs, but effective 
delivery methods are not yet available. Triggering of antitumor 
immune responses can be achieved using Freund’s incomplete 
adjuvant, but due to poor tumour specific cytotoxic T cell induction 
and adverse side effects, a superior method is desirable. A report by 
Yoshikawa et al. showed that use of biodegradable poly (γ-glutamic 
acid)-based (γ-PGA) nanoparticles greatly elicited a potent immune 
response without adverse side effects [81]. The γ-PGA nanoparticles 
efficiently translocate from endosome into the cytosol for efficient 
MHC class I Ag presentation. As γ-PGA nanoparticles enhance Ag 
presentation, CD8+ T cells are promoted to differentiate into cytotoxic 
T cells, displaying antitumor activity. Hence γ-PGA nanoparticles 
are used widely in Ag delivery based tumor vaccines [81]. Though 
the mechanism of immune response has been extensively researched, 
further investigation regarding the intricate mechanism of γ-PGA 
nanoparticles in activating the TLR and adaptive immunity is required. 
 From the age old concept of immunology, both CTLs and NK 
cells are employed for eliciting antitumor immunity [79]. Exogenous 
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administration of poly (I:C), a TLR 3 agonist resulted in tumor 
regression with the activation of NK and CTLs [82]. This method of 
TLR 3 agonist targeting has been used in a number of different studies 
for triggering of apoptosis in tumor cells [83,73]. 
An interesting study by Stone et al. showed that when CD40 and 
TLR agonists were combined on a single platform they generated 
a much stronger immune response. Other notable effects of this 
combinatory approach resulted in elicitation of potent tumour-specific 
CD8+ T cells These findings highlighted the concept of long lasting 
immunological memory against tumor through elicitation of effector 
T cells [84]. 
Transition of DCs from immunosuppressive stage to 
immunostimulatory state by immunostimulants is also necessary 
for effective immunological response. The production of IL-12p70 
(IL-12 in a biologically active form with two subunits p35 and p40) 
is accomplished by synergistic use of two TLR agonists viz poly (I:C) 
and R-848 for the activation of TLR 3 and TLR 7/8 respectively. 10-
100 fold increase in IL-12p70 was noticed upon addition of CD40L. 
CD40L is used additionally since they enhance CD+8 T-cell responses 
TLR 2, 3, 9
VIRAL 
INFECTION DCs with Ag
IFN-1 NK cells + 
Infected 
cells











DCs with TLR NP 
MRI ScanMRI
Figure 2: Highly active retroviral therapy (HAART) of p24 Ag from HIV virus is engineered with TLR 3 and encapsulated to form microcapsule. This formulation results 
in increased production of chemokines. When this preparation is supplemented along with HAART, the fold of T cells doubled which is the positive response in HIV 
patients.  When HIV epitope peptide is coupled with TLR2/6, TLR 3, TLR 9 the avidity of Ag is increased. Viral infection leads to IFN-1 release by APCs. As a result 
NK cells get activated to lyse the viral infected cells. Mean while clonal expansion of CD4+ and CD8+ cells takes place to combat the infection. Advantage of this 
TLR mediated vaccine is the level of IFN-1 which is shown to be elevated after the treatment.   Use of magnetic nanoparticle core [MnO] with incorporation of CpG 
ODN using phosphoramidite enables trafficking of TLR nanoparticles. Photodection is enabled by introducing rhodamine into polymer chain. Location of magnetic 
nanoparticle with rhodamine can be visualised by MRI. The dual role of imaging and eliciting immunity is the catch of this technique.
TLR type Function
TLR 1+ TLR 6 Recognises triacyl peptides [11]. Decreases infection related morbidity and mortality. Necessary for good vaccine response [92].
TLR2 in complex with TLR1 or TLR6 Lipoproteins and lipopeptides recognition [12,25]
TLR3 Viral double-stranded RNA recognition and trigger apoptosis directly [13].
TLR4 Lipopolysaccharide recognition [15]Germinal centre formation, Ig maturation [93], Neuroinflammation and brain damage [94]. 
TLR5 Flagellin recognition [30]Protect the intestine from commensal bacteria [95]
TLR7 or TLR8 Single-stranded RNA recognition [17]Chemoresistance [96].
TLR9 Microbial DNA recognition [18]
TLR 10 Only human TLR without any agonist or function [97].
TLR 11 Preventing infection to internal organs of urinogenital system [20].
TLR 12 Unknown [21]
TLR 13 Unknown  [21]
Table 1: Functions of various TLRs.
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[85]. Though many successful vaccines induce persistent antibody 
responses, the above strategy holds best for the induction of robust 
immunity. 
TLR immunity against viruses
Viral infections are often not cleared entirely from the body unlike 
bacterial infections. There is a major global threat from viral infections 
such as Human Immuno deficiency Virus [HIV], Ebola, Avian 
Influenza Virus and West Nile Virus. Prevention using vaccination is 
critical for such infections, since only a few viral medicines are available. 
TLR responsiveness to viral glycoproteins has been reported in many 
cases. Viral nucleic acid sensing TLRs are endosomal and hence viral 
nucleic acid has to be taken up by APC’s for processing and signalling. 
TLR 3 and TLR 9 play the most important role in viral immunity. TLR 
3 recognises the viral double stranded RNA and TLR 9 perceives the 
non-methylated CpG dinucleotides present both in viral and bacterial 
genome [43]. Other TLRs such as TLR 7 and 8 also plays a crucial role 
in viral immunity. They initiate IFN–α and IFN-β production in DCs 
and monocytes through IRAK-4 TLR adaptor [86]. Studies show that 
virus can elicit both innate and adaptive immunity by TLR dependent 
and independent pathways. Delivery of appropriate TLR agonist for 
viral immunity through a nanovehicle is a challenging task. Several 
nanovehicles have been studied extensively. Nanocarrier systems made 
of calcium phosphate are preferred as a biomedical carrier due to the 
wide use of this material in biomedical application. It has been shown 
that calcium phosphate with CpG coated by a viral peptide Influenza 
A virus hemagglutinin [HA] serve as a potent antiviral vaccine. In 
nanoformulations these calcium phosphate particles are readily taken 
by cells and rapidly driven out without altering the intracellular levels 
of calcium [87]. 
Haes et al. researched on synergising p24 Ag (HIV) with TLR 
3 ligand poly (I:C) on monocyte derived DC cells. This showed an 
increased response of CCR7, CD80, CD83, CD86 and IL-12 (Figure 2). 
This study described the use of biodegradable microcapsule composed 
of poly electrolytes. Ovalbumin was used as an exemplary Ag for 
encapsulation into these microparticles to promote Ag presentation 
by DCs to CD4+ and CD8+ cells. Electrostatic interactions between 
microcapsules and TLRs stimulated the production of IL-12 and IFN-
1 from DCs]. IFN helps to keep the HIV viral load down by inducing 
T helper and cytotoxic T lymphocytes. Thus microcapsules act as an 
efficacious Ag delivery vehicle in the field of HIV vaccination. Use of 
HIV envelope protein and ligands for TLR2/6, TLR 3, TLR 9 increased 
the functional avidity of Ags compared with using ligands for only two 
of above mentioned TLR for clearance of virus from the host [88].
The majority of vaccines against sexually transmitted disease are 
given parentally, eliciting a high immune response. Vaccine against 
genital herpes is designed with the knowledge that DCs, epithelial cells 
of vagina and cervical mucosa express TLR2. Delivering TLR 2 agonist 
induces protective immunity against this disease. Newly designed 
vaccine contains Herpes Simplex Virus type 2 (HSV2), CD8+ T cell 
peptide epitope with palmitic acid (TLR agonist). When the above 
formulation was administered to wild type B6 which is TLR 2 /MD88 
deficient, the mice produced HSV 2 specific memory CD8+ cytotoxic T 
cell in genital tract and in spleen [89,90]. This self adjuvanting vaccine 
can be improved by the employment of nanoparticle to enhance 
prolonged circulation time in the blood. Advances in nanotechnology 
have pushed forwarded the synthesis of magnetic nanoparticles for the 
theragnostics.  
The core of the magnetic nanoparticle is commonly made of 
MnO to which ssDNA is incorporated by phospharamidite. The 
chromophore [rhodamine] is attached to the polymer chain for 
imaging. The incorporated ssDNA efficiently elevates TLR 9 pathway 
for enhancing the antiviral immunity. This novel approach is gaining 
importance for its optical and magnetic resonance properties [91].
Conclusions
Though targeting DCs using TLRs signalling is still in its infancy, it 
is considered as a very promising technology. Nanodelivery is a suitable 
method due to rapid and efficient uptake by DCs, and subsequently 
potent immune responses can be achieved. Co-delivery of cancer 
associated Ags and TLR agonist loaded nanoparticle has been shown to 
generate potent immune response. Understanding how these delivery 
systems affects the mechanism of DCs in stimulating naive T cells is 
limited and needs further research. In addition, cellular and molecular 
mechanisms behind these immune responses are not completely 
understood, and some immunotherapy studies have led to development 
of autoimmune conditions in patients. Therefore identification of those 
molecular triggers involved in innate and adaptive immune systems 
may revolutionise cancer treatments and vaccine technologies. Once 
a greater understanding of these signaling pathways has been gained, 
more effective treatments could include combinations of agents that 
trigger multiple immunologic pathways. 
Future Perspectives
Prevention is better than cure, yet it is difficult to prevent certain 
disease to which our body is prone. Considerable attention has been 
given to TLRs over the last decade, furthering our theoretical and 
mechanistic understanding of innate and adaptive immunity. A 
current need is to produce safe, immune potentiators or adjuvants 
using TLRs. The cornea serve as an ideal model for TLR exploration and 
experimentation as it is easily accessible and enjoys relative immune 
privilege. Opportunistic diseases like HIV can be addressed through 
TLRs with the hope of potential treatment development. Further studies 
on this molecular target will increase our understanding of TLRs. In 
the future we may see clinicians employing selective TLR ligands as an 
adjuvant to generate tolerance or utilizing small molecules to modulate 
TLR signaling in the prevention or treatment of various disorders.
Executive Summary
•	 Dendritic cells induce T cell response and indirectly elicit 
adaptive immunity.
•	 Toll like receptor recognise pathogens through pathogen 
associated molecular patterns.
•	 IL-1 receptor studies led to the insight of TLR.
•	 The three phase in which tumour escapes: elimination phase, 
equilibrium phase and escape phase.
•	 Human’s express TLR 1-10 gene, TLR 11, TLR 12, TLR 13 gene 
has been found to explicit in animals.
•	 TLRs are used as adjuvants to trigger dendritic cell maturation, 
leukocyte migration, release of chemokines and cytokines for 
enhanced immunity.
•	 Corneal angiogenesis studies are conducted in rabbit eyes. 
Cornea express most of the TLRs.
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•	 Corneal haziness can be sorted out in humans by use of TLRs 
in combination with nanoparticles.
•	 Nanoparticle drugs conjugated with PEG follows EPR effect 
and found to be efficient in combating tumour.
•	 Viral immunity is attained by employing TLRs. Even the 
dreadful virus HIV is combated using TLR ligands.
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